July 19, 2024
Top-line Data on RESTORE Study of Optogenetic Therapy for Retinitis Pigmentosa Presented at ASRS
Thirty percent of patients maintained 3-line vision gain.
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/yrbnrfey/cover_july_aug25.jpg
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/0amghqej/cover_julyaug25.jpg
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/rnjiohrl/cover_june25_web.jpg
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/5isnzmog/0725-op-cover-final-1.jpg
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/upwdjelf/0725_cover_final.jpg
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/aqbjxwjw/pp-cover.jpg
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/npjdtl1w/cp_november_cover.jpg
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/mvqdq2hc/nrp_cover_october_2024.jpg
July 19, 2024
Thirty percent of patients maintained 3-line vision gain.
By Jennifer Ford, content director
July 18, 2024
Younger, asymptomatic siblings of Stargardt patients maintained vision.
By Jennifer Ford, content director
July 18, 2024
The axitinib implant demonstrated both safety and efficacy.
By Jennifer Ford, content director
July 17, 2024
Patients showed a durable improvement of vision with 93% remaining injection free.
By Jennifer Ford, content director
July 17, 2024
Two-thirds of eyes remained supplement free.
By Jennifer Ford, content director
July 17, 2024
Data from the RHONE-X extension trial, presented for the first time at the meeting, show that Vabysmo maintained safety and efficacy over 4 years.